News & Updates

Adding anlotinib to gefitinib significantly improves progression-free survival (PFS) in treatment-naïve Chinese patients with EGFR-mutated (EGFRmut) advanced non-small-cell lung cancer (NSCLC), according to the results of the FL-ALTER phase III study.

Addition of daratumumab to the bortezomib, cyclophosphamide, and dexamethasone (VCD) regimen provides deeper haematological responses and improves progression-free survival (PFS) in patients with newly diagnosed myeloma who are not eligible for autologous stem cell transplantation (ASCT), according to the results of the AMaRC 03-16 phase II study.

Treatment with carboplatin-paclitaxel (CP) plus atezolizumab results in better quality-adjusted survival in patients with advanced or recurrent endometrial cancer (EC) as compared with CP alone, according to a post hoc analysis of the AtTEnd/ENGOT-EN7 trial.

In untreated myelofibrosis, using navitoclax in combination with ruxolitinib appears to result in a twofold increase in the number of patients experiencing spleen volume shrinkage, regardless of prognosis, according to updated data from the phase III TRANSFORM-1 trial.

Use of artificial intelligence (AI)-assisted cancer contours helps minimize underestimation of the extent of prostate cancer, thereby improving the physician’s ability in terms of contouring accuracy and negative margin rate, a study has shown.

American Society of Clinical Oncology (ASCO) 2024: 5-year data from the international, randomized, open-label phase III CROWN trial comparing lorlatinib vs crizotinib in treatment-naïve patients with advanced ALK+ non-small-cell lung cancer (NSCLC) demonstrate unprecedented progression-free survival (PFS) with lorlatinib.